Partner Content Partner Content Ensuring a more informed and effective oncology drug develop... The rush to discover the next big frontier in cancer medicine is more evident than it ever has been since the introduction of targeted therapies.
Articles Healthcare systems aren’t making the most of biosimilars: ph... Biosimilars could save European and US healthcare systems billions - but more needs to be done to maximise their benefits, writes Richard Staines.
Articles Can Novo Nordisk’s pipeline transform obesity treatment? Novo Nordisk's pipeline drugs show 'astonishing' weight-loss effects – but can it convince sceptical payers that medicines are the answer to the obesity epidemic?
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.